Resources from the same session
1O - Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: a randomized, double-blind, multi-center, phase III study (FURLONG)
Presenter: Yuan-Kai Shi
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
80O - Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: sub-analysis from the pivotal phase III IMpower010 study
Presenter: Enriqueta Felip
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
141O - Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: characteristics of long-term survivors in the CASPIAN study
Presenter: Niels Reinmuth
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
Q&A
Session: Proffered Paper session
Resources:
Webcast
Invited Discussant of 80O and 141O
Presenter: Federico Cappuzzo
Session: Proffered Paper session
Resources:
Slides
Webcast
Q&A
Session: Proffered Paper session
Resources:
Webcast